| scholarly article | Q13442814 |
| P50 | author | Elizabeth A Kelly | Q55094086 |
| Mats W. Johansson | Q55094089 | ||
| Nizar N Jarjour | Q88330675 | ||
| Sameer Mathur | Q88895109 | ||
| Stephane Esnault | Q42777061 | ||
| Michael D. Evans | Q43090931 | ||
| P2093 | author name string | Deane F Mosher | |
| Loren C Denlinger | |||
| Lin Ying Liu | |||
| P2860 | cites work | Activation states of blood eosinophils in asthma | Q26853383 |
| Adhesion-induced eosinophil cytolysis requires the receptor-interacting protein kinase 3 (RIPK3)-mixed lineage kinase-like (MLKL) signaling pathway, which is counterregulated by autophagy | Q46382543 | ||
| Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial | Q47249808 | ||
| Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions | Q47890299 | ||
| Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics | Q47963812 | ||
| Mepolizumab treatment in patients with severe eosinophilic asthma | Q48065984 | ||
| The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia | Q48117814 | ||
| Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. | Q51563764 | ||
| Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. | Q51611177 | ||
| Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. | Q51699006 | ||
| Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. | Q51699174 | ||
| CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines | Q55094049 | ||
| Anti–IL-5 (mepolizumab) therapy does not alter IL-5 receptor α levels in patients with eosinophilic esophagitis | Q61959741 | ||
| Allergen-induced asthmatic responses. Relationship between increases in airway responsiveness and increases in circulating eosinophils, basophils, and their progenitors | Q68189016 | ||
| Increased airway inflammation with segmental versus aerosol antigen challenge | Q70457990 | ||
| Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma | Q73728083 | ||
| Effect of inhaled interleukin-5 on eosinophil progenitors in the bronchi and bone marrow of asthmatic and non-asthmatic volunteers | Q80505531 | ||
| Human airway and peripheral blood eosinophils enhance Th1 and Th2 cytokine secretion | Q83185052 | ||
| Theirs but to die and do: primary lysis of eosinophils and free eosinophil granules in asthma | Q87262417 | ||
| Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge | Q28215560 | ||
| Random-effects models for longitudinal data | Q28279619 | ||
| Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells | Q29618163 | ||
| Eosinophil granules function extracellularly as receptor-mediated secretory organelles | Q30484748 | ||
| Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. | Q30537562 | ||
| Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules | Q33669090 | ||
| Identification of genes expressed by human airway eosinophils after an in vivo allergen challenge. | Q34356793 | ||
| Eosinophil secretion of granule-derived cytokines. | Q34406828 | ||
| Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma | Q34542340 | ||
| Lower airway rhinovirus burden and the seasonal risk of asthma exacerbation | Q35528312 | ||
| Piecemeal degranulation in human eosinophils: a distinct secretion mechanism underlying inflammatory responses | Q36188927 | ||
| Anti-IL-5 attenuates activation and surface density of β(2) -integrins on circulating eosinophils after segmental antigen challenge. | Q36630280 | ||
| Human eosinophil activin A synthesis and mRNA stabilization are induced by the combination of IL-3 plus TNF. | Q37165737 | ||
| Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels | Q37358879 | ||
| Haemopoietic processes in allergic disease: eosinophil/basophil development | Q37557714 | ||
| Semaphorin 7A is expressed on airway eosinophils and upregulated by IL-5 family cytokines | Q37625993 | ||
| Mepolizumab and exacerbations of refractory eosinophilic asthma | Q37711391 | ||
| Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody | Q37846670 | ||
| Eosinophil granule proteins: form and function | Q38209847 | ||
| In situ hematopoiesis: a regulator of TH2 cytokine-mediated immunity and inflammation at mucosal surfaces | Q38382162 | ||
| A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis | Q38422089 | ||
| Mepolizumab: First Global Approval | Q38646902 | ||
| Human eosinophils release IL-1ß and increase expression of IL-17A in activated CD4+ T lymphocytes | Q39464920 | ||
| Clinical control of asthma associates with measures of airway inflammation | Q39540797 | ||
| CD44 and CD69 represent different types of cell-surface activation markers for human eosinophils | Q41031721 | ||
| Potent synergistic effect of IL-3 and TNF on matrix metalloproteinase 9 generation by human eosinophils | Q41909413 | ||
| Human airway smooth muscle promotes eosinophil differentiation | Q42170514 | ||
| RNA Seq profiling reveals a novel expression pattern of TGF-β target genes in human blood eosinophils. | Q42776997 | ||
| The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects | Q44058571 | ||
| Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process | Q44223903 | ||
| Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. | Q44247874 | ||
| Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alph | Q44448872 | ||
| Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma | Q44715380 | ||
| Local proliferation and mobilization of CCR3(+) CD34(+) eosinophil-lineage-committed cells in the lung | Q45350681 | ||
| Mepolizumab for prednisone-dependent asthma with sputum eosinophilia | Q46098864 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | asthma | Q35869 |
| phenotype | Q104053 | ||
| mepolizumab | Q3306175 | ||
| P304 | page(s) | 1385-1395 | |
| P577 | publication date | 2017-12-01 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma | |
| P478 | volume | 196 |
| Q93222121 | Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2 |
| Q58698606 | Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use |
| Q52564875 | Biologic Targeting: New and Effective Therapeutic Approaches against Severe Asthma. |
| Q89027053 | Characterization of Siglec-8 Expression on Lavage Cells after Segmental Lung Allergen Challenge |
| Q90044919 | Club Cell TRPV4 Serves as a Damage Sensor Driving Lung Allergic Inflammation |
| Q93147066 | Comparison of IL-33 and IL-5 family mediated activation of human eosinophils |
| Q64113098 | Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors? |
| Q92157691 | Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab |
| Q64072061 | Hydroxysafflor Yellow A Alleviates Ovalbumin-Induced Asthma in a Guinea Pig Model by Attenuateing the Expression of Inflammatory Cytokines and Signal Transduction |
| Q58693435 | Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview |
| Q64057019 | Intravital imaging allows real-time characterization of tissue resident eosinophils |
| Q57490103 | Involvement and Possible Role of Eosinophils in Asthma Exacerbation |
| Q52715985 | Matrix protein Tenascin C expands and reversibly blocks maturation of murine eosinophil progenitors. |
| Q92149412 | Mepolizumab does not alter the blood basophil count in severe asthma |
| Q92504767 | Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis |
| Q55131660 | Proteomic and Phosphoproteomic Changes Induced by Prolonged Activation of Human Eosinophils with IL-3. |
| Q92309205 | Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report |
| Q52719312 | Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease. |
| Q52571066 | Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma. |
Search more.